Topic
Pharmaceuticals
1,003 published works
Spicy IP
Remembering Mr. P. H. Kurian (1959-2026)
Mr. P. H. Kurian (1959-2026) It is with great sorrow that we share that the Indian IP fraternity lost one of its most remarkable administrators, Mr. P. H. Kurian, yesterday…
Drug & Device Law
State of the States (Rankings, part 2)
Last week we reviewed our 2020-25 Best and Worst lists to see if any patterns emerged in terms of the federal circuits. Our tentative conclusions were that the Fifth Circuit…
Big Molecule Watch
Biocon Launches Aflibercept Biosimilar in the United States
On August 3, 2026, Biocon Limited announced the commercial launch of its biosimilar YESAFILI (aflibercept-jbvf) in the United States. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor that is…
Spicy IP
Mavyret Patent Abandonment Does Not Open the Field for Hepatitis C Generics
July 28, 2026 marked eight years of the National Viral Hepatitis Control Program (NVHCP). Launched under the National Health Mission, the program aims to eliminate Hepatitis C from India by…
Rivkin Rounds
Kaiser to Present on Navigating Legal Challenges in Drug and Device Industries
On September 17, Rivkin Radler's Jeff Kaiser will participate on a panel at the Practising Law Institute (PLI) "Life Sciences 2026: Navigating Legal Challenges in Drug and Device Industries" program…
Searcy Law Blog
How Can Patients Sue for Harm Caused By Drugs and Medical Devices?
By Searcy Law
Suing for harm caused by a dangerous drug or medical device often involves pursuing mass tort litigation. In mass tort litigation, multiple patients—potentially hundreds or thousands—pursue similar claims for just…
Spicy IP
One Atomic Substitution, Two Giant Hurdles of Disclosure and Efficacy
By SpicyIP
In Intra Cellular Therapies v. Controller of Patents, the Delhi High Court revisited two recurring fault lines in pharmaceutical patent law: the coverage disclosure distinction in genus-species claims and the…
India Corporate Law
Significant Ruling on Combination Patents: Delhi High Court Highlights Inventive Step and Patentability Criteria
Summary: In Array BioPharma Inc. v Deputy Controller of Patents, the Delhi High Court set aside the Controller’s refusal of Array BioPharma’s combination patent application and remanded it for fresh consideration.…
Drug & Device Law
A British Hi-Tech Response to a Hi-Tech Problem
By Bexis
Novo Nordisk A/S v. British Telecommunications Plc, 2026 WL 01791875 (Ch. Div. June 23, 2026), is the first judicial decision from the United Kingdom that we have featured on the…
Big Molecule Watch
Fresenius Kabi and Dr. Reddy’s Announce FDA Approval of Rituximab Biosimilar
By Sam Herron
On August 1, 2026, Fresenius Kabi and Dr. Reddy’s Laboratories announced that the FDA had approved Dr. Reddy’s rituximab biosimilar, a biosimilar to Genentech’s RITUXAN® (rituximab). Rituximab is a monoclonal…